Aurinia Pharmaceuticals Inc AUPH
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Trading Information
- Previous Close Price
- $16.22
- Day Range
- $16.12–16.97
- 52-Week Range
- $10.90–19.25
- Bid/Ask
- $16.69 / $16.80
- Shares Outstanding
- 133.05M
- Market Cap
- $2.22B
- Volume/Avg
- 849,427 / 984,464
Key Statistics
- Price/Earnings (Normalized)
- 7.26
- Price/Sales
- 7.29
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- 3.77%
Company Profile
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing aritinercept, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 128
- Website
- https://www.auriniapharma.com
Valuation
|
Metric
|
AUPH
|
|---|---|
Price/Earnings (Normalized) | 7.26 |
Price/Book Value | 3.60 |
Price/Sales | 7.29 |
Price/Cash Flow | 12.89 |
Price/Earnings
AUPH
Financial Strength
|
Metric
|
AUPH
|
|---|---|
Quick Ratio | 4.85 |
Current Ratio | 5.42 |
Interest Coverage | 36.71 |
Quick Ratio
AUPH
Profitability
|
Metric
|
AUPH
|
|---|---|
Return on Assets (Normalized) | 49.44% |
Return on Equity (Normalized) | 66.14% |
Return on Invested Capital (Normalized) | 56.12% |
Return on Assets
AUPH
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|n<xpXg& | LOCK|fC&N | $129B | |||
| Moderna Inc
MRNA
| LOCK|d$q<!!T | LOCK|r# | $90B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|yF!Y$@! | LOCK|tH!Vw | $77B | |||
| argenx SE ADR
ARGX
| LOCK|S@g#Z! | LOCK|DV@ | $51B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|LYT^v$# | LOCK|!F& | $41B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|QcS<<?j | LOCK|!pJ^G | $31B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|<t<bf%<z | LOCK|mJKD | $25B | |||
| BioNTech SE ADR
BNTX
| LOCK|D#SgDX | LOCK|xz^ | $24B | |||
| Incyte Corp
INCY
| LOCK|#>!&<?R | LOCK|M<h | $23B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|Ls&#&nV | LOCK|$>^ | $14B |
United States